Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P49721
UPID:
PSB2_HUMAN
Alternative names:
Macropain subunit C7-I; Multicatalytic endopeptidase complex subunit C7-I; Proteasome component C7-I
Alternative UPACC:
P49721; D3DPS0; P31145; Q9BWZ9
Background:
The Proteasome subunit beta type-2, known by alternative names such as Macropain subunit C7-I, Multicatalytic endopeptidase complex subunit C7-I, and Proteasome component C7-I, plays a pivotal role in cellular function. It is a non-catalytic component of the 20S core proteasome complex, crucial for the proteolytic degradation of intracellular proteins. This degradation is essential for maintaining protein homeostasis, removing misfolded or damaged proteins, and regulating protein levels necessary for cellular functions.
Therapeutic significance:
Understanding the role of Proteasome subunit beta type-2 could open doors to potential therapeutic strategies. Its involvement in the ATP-dependent degradation of ubiquitinated proteins and ubiquitin-independent protein degradation pathways highlights its importance in cellular health and disease prevention.